KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Long-Term Debt Repayments (2019)

Castle Biosciences (CSTL) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $802000.0 as the latest value for Q2 2019.

  • Quarterly Long-Term Debt Repayments changed N/A to $802000.0 in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $802000.0 through Mar 2020, changed N/A year-over-year, with the annual reading at $1.8 million for FY2019, N/A changed from the prior year.
  • Long-Term Debt Repayments hit $802000.0 in Q2 2019 for Castle Biosciences, down from $989000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $989000.0 in Q1 2019 to a low of $802000.0 in Q2 2019.